Pfizer Inc. $PFE Shares Sold by Obermeyer Wealth Partners

Obermeyer Wealth Partners lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 11.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 29,512 shares of the biopharmaceutical company’s stock after selling 3,696 shares during the quarter. Obermeyer Wealth Partners’ holdings in Pfizer were worth $715,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the stock. Brighton Jones LLC lifted its holdings in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Pfizer in the first quarter valued at about $223,000. Brookstone Capital Management grew its stake in Pfizer by 7.0% during the 1st quarter. Brookstone Capital Management now owns 116,746 shares of the biopharmaceutical company’s stock valued at $2,958,000 after purchasing an additional 7,593 shares in the last quarter. Finally, World Investment Advisors increased its holdings in Pfizer by 14.2% during the 1st quarter. World Investment Advisors now owns 153,435 shares of the biopharmaceutical company’s stock worth $3,888,000 after purchasing an additional 19,057 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on PFE shares. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. UBS Group reissued a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Sanford C. Bernstein restated a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a research note on Friday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Finally, Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $28.24.

Pfizer Stock Up 1.6%

Pfizer stock opened at $24.68 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a one year low of $20.92 and a one year high of $28.64. The company has a 50-day simple moving average of $24.77 and a 200-day simple moving average of $24.30. The firm has a market capitalization of $140.29 billion, a P/E ratio of 13.13, a P/E/G ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period in the previous year, the business posted $0.60 EPS. Pfizer’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.